Cipla Limited has notified stock exchanges regarding USFDA inspection observations received by its US subsidiary InvaGen Pharmaceuticals. The regulatory development comes following a Pre-Approval Inspection conducted at the company's New York manufacturing facility.

Inspection Details and Timeline

The United States Food and Drug Administration conducted a Pre-Approval Inspection at InvaGen Pharmaceuticals' manufacturing facility located in Hauppauge, Long Island, New York, USA. The inspection was carried out over an eight-day period from February 2nd to 9th, 2026.

USFDA Observations Received

Upon conclusion of the inspection, InvaGen Pharmaceuticals received 2 inspection observations documented in Form 483. Form 483 is the standard document used by the USFDA to communicate observations noted during facility inspections that may constitute violations of the Food, Drug and Cosmetic Act and related regulations.

Company Response and Commitment

Cipla has indicated its commitment to addressing the inspection observations comprehensively. The company stated it will work closely with the USFDA to resolve the identified issues within the stipulated timeframe. This collaborative approach demonstrates the company's focus on maintaining regulatory compliance for its US operations.

Regulatory Disclosure

The notification was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary Rajendra Chopra signed the disclosure document on February 10th, 2026, ensuring timely communication to all relevant stock exchanges including BSE Limited, National Stock Exchange of India Limited, and Societe de la Bourse de Luxembourg.

Cipla Limited has allotted 8,879 equity shares under its employee stock option schemes, marking another step in its employee compensation programs. The pharmaceutical company informed stock exchanges about this corporate action on January 28, 2026, in compliance with regulatory requirements.

Share Allotment Details

The Operations and Administrative Committee of Cipla approved the allotment of 8,879 fully paid-up equity shares on January 28, 2026. These shares were issued pursuant to the exercise of employee stock options and stock appreciation rights under two specific schemes.

Employee Stock Option Schemes

The share allotment was executed under two employee compensation schemes:

• Employee Stock Option Scheme 2013-A: A long-standing equity compensation program for employees
• Cipla Employee Stock Appreciation Rights Scheme 2021: A more recent scheme offering stock appreciation rights to eligible employees

These schemes are designed to provide equity-based compensation to employees, aligning their interests with shareholders and supporting employee retention.

Impact on Share Capital

Following the allotment, Cipla's capital structure has been updated to reflect the additional shares issued.

Regulatory Compliance

Cipla has notified multiple stock exchanges about this allotment in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed:

• BSE Limited (Scrip Code: 500087)
• National Stock Exchange of India Limited (Scrip Code: CIPLA)
• Societe de la Bourse de Luxembourg

The company also copied Central Depository Services (India) Limited and National Securities Depository Limited on the communication, ensuring all relevant depositories are informed of the capital structure changes.

This allotment represents a routine corporate action as part of Cipla's ongoing employee compensation programs, reflecting the company's commitment to equity-based employee incentives.